Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

20182,300 citationsJournal Articlebronze Open Access

Authors

Ghassan K. Abou‐Alfa · Memorial Sloan Kettering Cancer Center

Tim Meyer · University College London

Ann‐Lii Cheng · National Taiwan University Hospital

Anthony B. El-Khoueiry · USC Norris Comprehensive Cancer Center

Lorenza Rimassa

Baek‐Yeol Ryoo · Asan Medical Center

İrfan Çiçin · Trakya University

Abstract

Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. The rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group. (Funded by Exelixis; CELESTIAL ClinicalTrials.gov number, NCT01908426 .).

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Pancreatic and Hepatic Oncology Research Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 1, pp. 54-63

DOI: 10.1056/nejmoa1717002

Field-Weighted Citation Impact: 137.99